Generic Companies with Tentative Approvals for: Hetero Labs Ltd Iii

« Back to Dashboard

Hetero Labs Ltd Iii Generic Filers with Tentative Approvals

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or try a Free Trial
Applicant	Generic Name	NDA	Strength	Dosage Form
Hetero Labs Ltd Iii	raltegravir	203540	400MG	TABLET;ORAL
Hetero Labs Ltd Iii	lopinavir; ritonavir	091677	200MG; 50MG	TABLET; ORAL
Hetero Labs Ltd Iii	lamivudine	091475	10MG/ML	SOLUTION; ORAL
Hetero Labs Ltd Iii	lamivudine; tenofovir disoproxil fumarate; nevirapine	205355	300MG; 300MG; 200MG	TABLET; ORAL
Applicant	Generic Name	NDA	Strength	Dosage Form

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.